Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

EPR PropertiesTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Neurocrine Biosciences Inc — how do they compare? EPR Properties trades at $61.2 (market cap $4.58B), while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.6× EPR Properties's market cap, and EPR Properties pays a 6.22% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

EPRNBIX
Market Cap
$4.58B$16.46B
Sector
Real EstateHealth
52-Week High
$64.32$185.50
52-Week Low
$48.71$123.10
Enterprise Value
$8.09B$16.48B
Dividend Yield
6.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties (EPR) trades at $61.41, up 1.67% in the last session, with a bearish technical signal despite strong Q2 2026 FFO beating estimates. The company reported revenue growth to $699 million in 2026, though net income dipped to $263 million, and maintains a high gross margin of 91.41%. Recent news highlights dividend declarations and a new $1.6 billion credit facility, supporting its experiential real estate focus.

Outlook is mixed: analyst consensus favors 'Hold' with a $65.30 price target, indicating modest upside, but technical indicators and a slight earnings miss in Q1 2026 pose risks. Opportunities include dividend growth and portfolio diversification, while risks involve investing cash flow volatility and sector competition.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX